❓ Peptide Industry — Frequently Asked Questions (FAQ)¶

Q: What is the global peptide market size and what are the key growth drivers?

The global peptide market was approximately $45 billion in 2024 (including therapeutic drugs, cosmetic peptides, and food peptides), with a 2019–2024 CAGR of 8.5%. Core growth drivers include: explosive growth of GLP-1 drugs (55% of peptide market), maturation of oral delivery technologies, CDMO capacity release, and increasing chronic disease treatment demand. China's peptide API market is approximately ¥12.8 billion, representing about 35–40% of global share.

Q: What services do peptide CDMOs provide and how do you select a CDMO partner?

Peptide CDMOs provide end-to-end services from process development → GMP production → purification → lyophilization → quality analysis → regulatory filing support. Selecting a CDMO requires evaluating: synthesis technology capabilities (SPPS/LPPS/enzymatic), large-scale production capacity (reactor volume/annual capacity), quality certifications (NMPA/FDA/EU GMP), regulatory support capabilities, IP protection mechanisms, delivery timelines, and cost structure. On-site auditing and requesting quality documentation is recommended.

Q: What are the main regulatory agencies and requirements for China's peptide industry?

The primary regulatory agencies include NMPA (National Medical Products Administration), CDE (Center for Drug Evaluation), and local drug regulatory authorities. Core requirements: innovative drugs must follow the Drug Registration Regulation for IND/NDA filing; peptide generics require consistency evaluation; cosmetic peptides require NMPA filing with safety assessment reports; health food peptides require registration/filing. In 2024, CDE issued the 'Technical Guidelines for Quality Control of Peptide Drugs (Trial)', strengthening impurity analysis and stability requirements.

Q: What are the main quality standards for peptide active pharmaceutical ingredients (APIs)?

Peptide API quality standards primarily include: purity (typically ≥98.0%), individual impurity limits (generally ≤1.0%), total impurity limits (generally ≤3.0%), residual solvents (ICH Q3C), EPC/DPA impurity control, amino acid composition analysis, content determination, moisture, microbial limits, bacterial endotoxins, etc. EPC/DPA impurity control has become a recent regulatory focus. The Chinese Pharmacopoeia 2025 edition (ChP 2025) further refines general peptide standards.

Q: How is peptide drug pricing determined and what are the future trends?

Peptide drug pricing depends on molecular complexity, synthesis difficulty, market size, and competitive landscape. Annual treatment costs for innovative peptide drugs typically range from $10,000–$100,000/year. Generic/API pricing is more based on manufacturing cost plus reasonable margin. In 2024, GLP-1 API (non-GMP grade) market price was approximately $300–800/kg (depending on purity and scale), with GMP grade being higher. Future trends: 2026–2027 GLP-1 generic drug launches will drive prices down 30–50%; oral peptide R&D costs are high but formulation differentiation can maintain pricing premium.

Q: What are the core development trends for the peptide industry in the next 5 years?

Core trends include: (1) GLP-1 multi-target drugs (GLP-1/GIP/GCG triple agonists) entering late-stage clinical trials; (2) Continued breakthroughs in oral delivery technology with more oral peptide drugs reaching market; (3) China CDMO global share growing from 32% to 40%+ with accelerated capacity expansion; (4) Industrialization of green synthesis technologies (aqueous SPPS, continuous flow, enzymatic); (5) Rapid growth of cyclic peptide and PDC drug pipelines; (6) AI-assisted peptide design extending from early discovery to process development; (7) Price competition from GLP-1 generics reshaping the market landscape.

Q: What are the main challenges in controlling impurities during peptide synthesis?

The main challenges in peptide synthesis impurity control include: (1) Racemization — the chiral center of the C-terminal amino acid may racemize during coupling; (2) Deletion sequences — incomplete coupling produces byproducts with missing amino acids; (3) Insertion sequences (EPC) — repeated coupling of protected amino acids generating repeat sequences; (4) β-elimination products — dehydration of asparagine/glutamine forming cyclic imides; (5) Oxidation impurities — methionine, tryptophan, cysteine are prone to oxidation; (6) Aggregation/secondary structure-induced coupling difficulties — long peptides or poorly soluble sequences. Modern quality control relies on UPLC-MS/MS for impurity profiling, requiring CDMOs to have professional analytical method development capabilities.

Q: What are the core differences between peptide drugs and small-molecule chemical drugs?

Peptide drugs fall between small molecules ( 5000 Da): molecular weight typically 500–5000 Da, filling the 'chemical space' between them. Key differences include: (1) Targeting — peptides can form interface-level interactions with target proteins through multiple side chains, offering superior affinity and selectivity over small molecules; (2) Toxicity — peptides typically degrade into amino acids with lower metabolic safety risk than small molecules; (3) Stability — peptides are easily degraded by enzymes with low oral bioavailability; (4) Synthesis — peptide synthesis involves more steps, lower yields, and higher costs; (5) Route of administration — peptides are primarily injectable while small molecules are primarily oral.

Q: How do you evaluate a peptide CDMO's professional capabilities?

Key metrics for evaluating a peptide CDMO: (1) Technology platform — Is SPPS+Fmoc mature? Does it have advanced processes like microwave-assisted synthesis or continuous flow? (2) Capacity scale — Total solid-phase reactor volume, number of preparative HPLC systems, lyophilization capacity; (3) Quality system — Has it passed NMPA GMP? Does it hold FDA DMF filings/EU GMP certificates? (4) Project experience — Number of successful NDA/ANDA filings, types of clients served, longest synthesis sequence record; (5) Team capability — Experience and scale of process development scientists; (6) Compliance record — FDA/NMPA inspection history, any 483s or warning letters; (7) Value for money — Is the cost structure transparent? Is delivery reliable? On-site auditing and reference calls with existing clients are recommended.

Frequently asked questions about the peptide industry — market size, GLP-1 drugs, CDMO services, regulatory & quality, pricing, and future trends.

📋 FAQ Index¶

#	Question	Jump
1	What is the global peptide market size and what are the key growth drivers?	→
2	Why are GLP-1 drugs so popular and what is their market size?	→
3	What services do peptide CDMOs provide and how do you select a CDMO partner?	→
4	What are the main regulatory agencies and requirements for China's peptide industry?	→
5	What are the main quality standards for peptide active pharmaceutical ingredients (APIs)?	→
6	How is peptide drug pricing determined and what are the future trends?	→
7	What are the core development trends for the peptide industry in the next 5 years?	→
8	What are the main challenges in controlling impurities during peptide synthesis?	→
9	What are the core differences between peptide drugs and small-molecule chemical drugs?	→
10	How do you evaluate a peptide CDMO's professional capabilities?	→

1. What is the global peptide market size and what are the key growth drivers?¶

The global peptide market was approximately $45 billion in 2024 (including therapeutic drugs, cosmetic peptides, and food peptides), with a 2019–2024 CAGR of 8.5%. Core growth drivers include: explosive growth of GLP-1 drugs (55% of peptide market), maturation of oral delivery technologies, CDMO capacity release, and increasing chronic disease treatment demand. China's peptide API market is approximately ¥12.8 billion, representing about 35–40% of global share.

2. Why are GLP-1 drugs so popular and what is their market size?¶

GLP-1 receptor agonists were initially developed for type 2 diabetes treatment, then exploded in the market due to significant weight loss effects. Semaglutide (Novo Nordisk) had global sales of approximately $21.2B in 2024, and Tirzepatide (Eli Lilly) approximately $11.5B, together accounting for 55% of the total peptide market. Indications are expanding from diabetes/obesity to cardiovascular disease, NASH, chronic kidney disease, Alzheimer's disease, etc., with the market expected to surpass $80B by 2029.

3. What services do peptide CDMOs provide and how do you select a CDMO partner?¶

Peptide CDMOs provide end-to-end services from process development → GMP production → purification → lyophilization → quality analysis → regulatory filing support. Selecting a CDMO requires evaluating: synthesis technology capabilities, large-scale production capacity, quality certifications (NMPA/FDA/EU GMP), regulatory support capabilities, IP protection, delivery timelines, and cost structure.

4. What are the main regulatory agencies and requirements for China's peptide industry?¶

The primary regulatory agencies include NMPA, CDE, and local drug regulatory authorities. Core requirements: innovative drugs must file IND/NDA; peptide generics require consistency evaluation; cosmetic peptides require NMPA filing with safety assessment reports; health food peptides require registration/filing. In 2024, CDE issued the Technical Guidelines for Quality Control of Peptide Drugs (Trial).

5. What are the main quality standards for peptide active pharmaceutical ingredients (APIs)?¶

Primarily includes: purity (≥98.0%), individual impurities (generally ≤1.0%), total impurities (generally ≤3.0%), residual solvents (ICH Q3C), EPC/DPA impurity control, amino acid composition analysis, content determination, moisture, microbial limits, etc. The Chinese Pharmacopoeia 2025 edition (ChP 2025) further refines general peptide standards.

6. How is peptide drug pricing determined and what are the future trends?¶

Innovative peptide drug annual treatment costs $10K–$100K. In 2024, GLP-1 API (non-GMP grade) market price was approximately $300–800/kg. Future trends: 2026–2027 GLP-1 generics will drive prices down 30–50%; oral peptides will maintain higher pricing due to technology premiums.

7. What are the core development trends for the peptide industry in the next 5 years?¶

(1) GLP-1 multi-target drugs entering late-stage clinical trials; (2) Oral delivery technology breakthroughs; (3) China CDMO global share growing to 40%+; (4) Green synthesis industrialization; (5) Cyclic peptide and PDC pipeline growth; (6) AI-assisted peptide design; (7) GLP-1 generic price competition.

8. What are the main challenges in controlling impurities during peptide synthesis?¶

Includes racemization, deletion sequences, insertion sequences (EPC), β-elimination products, oxidation impurities, and aggregation issues. Modern quality control relies on UPLC-MS/MS for impurity profiling, requiring CDMOs to have professional analytical method development capabilities.

9. What are the core differences between peptide drugs and small-molecule chemical drugs?¶

Peptides fall between small molecules (<500 Da) and biologics (>5000 Da). Key differences: stronger targeting, higher metabolic safety, easily degraded by enzymes (low oral bioavailability), higher synthesis costs, primarily injectable administration.

10. How do you evaluate a peptide CDMO's professional capabilities?¶

Evaluation metrics include: technology platform (SPPS/LPPS/microwave-assisted), capacity scale (reactor volume/purification lines), quality system (NMPA/FDA/EU GMP), project experience (number of successful filings), compliance record (FDA 483/warning letters), value for money, and delivery timelines. On-site auditing is recommended.

More questions? If you have additional questions about the peptide industry, please contact the SENO Biotechnology industry analysis team. We provide peptide CDMO services and industry consulting. — Visit senopeptide.com/faq/ to submit your question